Literature DB >> 11170994

Proliferative responses to human immunodeficiency virus type 1 (HIV-1) antigens in HIV-1-infected patients with immune reconstitution.

J N Blankson1, J E Gallant, R F Siliciano.   

Abstract

Cell-mediated immunity is affected early in human immunodeficiency virus type 1 (HIV-1) infection. HIV-1-specific CD4+ T cell proliferative responses are not measurable in most patients but have been reported in long-term nonprogressors and in patients treated with highly active antiretroviral therapy (HAART) during primary infection. However, treatment with HAART generally does not restore HIV-1-specific CD4+ T cell responses in chronically infected patients. In this study, HIV-1-specific CD4+ T cell responses in 10 HIV-1-infected patients who began HAART with low CD4 cell count nadirs and experienced significant immune reconstitution were studied. Surprisingly, 5 of these patients had proliferative responses to > or =1 HIV-1 gene product, compared with 0 of 8 chronically infected patients who started HAART when their CD4 cell counts were still relatively high. These results suggest that, in some patients with advanced HIV-1 infection, treatment with HAART can lead not only to significant increases in CD4 cell counts but also to the restoration of HIV-1-specific responses.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11170994     DOI: 10.1086/318545

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  19 in total

1.  MHC class II genotype and the control of viremia in HIV-1-infected individuals on highly active antiretroviral therapy.

Authors:  J N Blankson; R F Siliciano
Journal:  J Clin Invest       Date:  2001-03       Impact factor: 14.808

2.  Memory responses in human immunodeficiency virus type 1-infected individuals with long-term viral load suppression are independent of CD4 cell nadir.

Authors:  Michael A Kolber; Maria O Saenz; Sameer Kaul
Journal:  Clin Diagn Lab Immunol       Date:  2005-01

3.  Low antigen-specific CD4 T-cell immune responses despite normal absolute CD4 counts after long-term antiretroviral therapy an African cohort.

Authors:  Rose Nabatanzi; Lois Bayigga; Isaac Ssinabulya; Agnes Kiragga; Andrew Kambugu; Joseph Olobo; Moses Joloba; Moses R Kamya; Harriet Mayanja-Kizza; Damalie Nakanjako
Journal:  Immunol Lett       Date:  2014-09-26       Impact factor: 3.685

4.  High-level HIV-1 viremia suppresses viral antigen-specific CD4(+) T cell proliferation.

Authors:  A C McNeil; W L Shupert; C A Iyasere; C W Hallahan; J A Mican; R T Davey; M Connors
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

Review 5.  Advances in understanding immunologic control of HIV infection.

Authors:  Stephen A Migueles; John C Tilton; Mark Connors
Journal:  Curr HIV/AIDS Rep       Date:  2004-04       Impact factor: 5.071

6.  HIV-1-specific CD4+ T lymphocyte turnover and activation increase upon viral rebound.

Authors:  Thomas J Scriba; Hua-Tang Zhang; Helen L Brown; Annette Oxenius; Norbert Tamm; Sarah Fidler; Julie Fox; Jonathan N Weber; Paul Klenerman; Cheryl L Day; Michaela Lucas; Rodney E Phillips
Journal:  J Clin Invest       Date:  2005-02       Impact factor: 14.808

7.  Diminished proliferation of human immunodeficiency virus-specific CD4+ T cells is associated with diminished interleukin-2 (IL-2) production and is recovered by exogenous IL-2.

Authors:  Christiana Iyasere; John C Tilton; Alison J Johnson; Souheil Younes; Bader Yassine-Diab; Rafick-Pierre Sekaly; William W Kwok; Stephen A Migueles; Alisha C Laborico; W Lesley Shupert; Claire W Hallahan; Richard T Davey; Mark Dybul; Susan Vogel; Julia Metcalf; Mark Connors
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

8.  The Role of CD4(+) and CD8(+) T Cells in Controlling HIV Infection.

Authors:  Stephen A. Migueles; Mark Connors
Journal:  Curr Infect Dis Rep       Date:  2002-10       Impact factor: 3.725

9.  Modulation of human immunodeficiency virus (HIV)-specific immune response by using efavirenz, nelfinavir, and stavudine in a rescue therapy regimen for HIV-infected, drug-experienced patients.

Authors:  Daria Trabattoni; Sergio Lo Caputo; Mara Biasin; Elena Seminari; Massimo Di Pietro; Giovanni Ravasi; Francesco Mazzotta; Renato Maserati; Mario Clerici
Journal:  Clin Diagn Lab Immunol       Date:  2002-09

10.  Immunity to human immunodeficiency virus (HIV) in children with chronic HIV infection receiving highly active antiretroviral therapy.

Authors:  Adriana Weinberg; Gregory B Pott
Journal:  Clin Diagn Lab Immunol       Date:  2003-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.